U.K. Cancer Research Program Aims at Bespoke Treatment, FT Says

The U.K. will start its first nationwide genetic testing program for cancer patients in September, with government, charitable and private commercial support, the Financial Times reported.

Cancer Research U.K. is leading the program, which is aimed at tailoring patients’ treatments to the genetic nature of their tumors, the newspaper said.

Initially, seven hospitals and three laboratories will collect and analyse 9,000 samples from six common cancers: breast, bowel, lung, prostate, ovary and melanoma; the samples will be tested for genes and mutations that have been identified as being likely to play a role in the development of the disease, the FT said.

That is likely to generate a coordinated program of personalised cancer treatment based on genetic testing, the newspaper said.

AstraZeneca Plc, Pfizer Inc. (PFE) and PA Consulting Group will be working with Cancer Research and the National Health Service on the project, the FT said.

To contact the reporter on this story: Alan Purkiss in London on apurkiss@bloomberg.net.

To contact the editor responsible for this story: Colin Keatinge at ckeatinge@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.